Question · Q3 2025
Ryan asked about the pace of new PFIC patient additions in Q3 2025 compared to Q2 2025, particularly concerning genetic testing and new diagnoses. He also sought insights into Mirum's business development strategy for adding more products to the pipeline, given consistent positive cash flow and upcoming launches.
Answer
President and COO Peter Radovich stated that the pace of PFIC adds remains healthy and broad, spanning infants to adults, driven by ongoing educational efforts to change the paradigm among adult providers regarding genetic cholestasis. CEO Chris Peetz emphasized that business development is core to Mirum's strategy, focusing on underappreciated programs with a high bar for value creation, but noted there is no urgency due to the company's strong financial position.